Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 6/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | MASP2 | O00187 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6088948 | 0.88 | PIKFYVE (0.37) | F9EPHX2PIKFYVEIDO1ESR1 | |
| SCHEMBL14039533 | 0.83 | F9 (0.36) | F9MAPK14EPHX2IDO1ESR1 | |
| SCHEMBL1690350 | 0.79 | F9 (0.43) | F9MAPK14EPHX2IDO1 | |
| SCHEMBL18302280 | 0.76 | EPHX2 (0.56) | EPHX2 | |
| SCHEMBL12012754 | 0.72 | NOS3 (0.39) | F9MAPK14IDO1LCKCSF1R | |
| SCHEMBL13893639 | 0.71 | NPC1 (0.38) | F9EPHX2IDO1ESR1ESR2 | |
| SCHEMBL21929348 | 0.70 | KDM4E (0.47) | F9MAPK14EPHX2IDO1ESR1 | |
| SCHEMBL8233882 | 0.70 | F9 (0.47) | F9MAPK14IDO1ESR1ESR2 | |
| SCHEMBL30765144 | 0.70 | ESR1 (0.58) | ESR1ESR2HSP90AA1 | |
| SCHEMBL16360885 | 0.70 | ESR1 (0.58) | ESR1ESR2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | ELI LILLY AND COMPANY (US) | 2006-10-19 | — | — | US | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | NR3C2, NR5A1, MC2R | F9 4128/4885MAPK14 1803/4885EPHX2 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.